Evidence map›Paper›PMID 41800116›Full record

ArticleLeukemia research reports2026

Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT.

Yasuyuki Takahashi, Ken Naganuma, Yuka Tanaka, Noriyuki Sakata, Taisuke Kawada, Masahiro Kizaki, Shuji Momose, Morihiro Higashi, Takayuki Tabayashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasuyuki TakahashiDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Ken NaganumaDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Yuka TanakaDepartment of Hematology, Otemae Hospital, Osaka, Japan.
Noriyuki SakataDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Taisuke KawadaDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Morihiro HigashiDepartment of Pathology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸F-FDG avidity (SUVmax 8.8), muscle enzymes remained normal, indicating a non-destructive "silent infiltrator" growth pattern. The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.

Indexed as

¹⁸F-FDG PET/CTAsymptomaticExtranodal LymphomaMalt lymphomaSkeletal muscle

Identifiers

PMID41800116
PMCPMC12966862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.